Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» PAH
PAH
Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival
Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival
Fierce Biotech
Gossamer Bio
layoffs
seralutinib
Merck
PAH
Flag link:
Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23
Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23
Endpoints
Merck
PAH
clinical trials
MK-0616
Flag link:
Gossamer's PAH Candidate Meets Primary Endpoint, Stumbles on Secondary Measure
Gossamer's PAH Candidate Meets Primary Endpoint, Stumbles on Secondary Measure
BioSpace
Gosamer Bio
PAH
seralutinib
Flag link:
Gossamer could put pressure on Merck
Gossamer could put pressure on Merck
EP Vantage
Merck
Gossamer Bio
PAH
sotatercept
United Therapeutics
ralinepag
Flag link:
Sotatercept- the breakthrough PAH has been waiting for?
Sotatercept- the breakthrough PAH has been waiting for?
Clinical Trials Arena
Merck
sotatercept
Acceleron
PAH
Flag link:
Is Merck Moving Toward Another Blockbuster Drug Launch?
Is Merck Moving Toward Another Blockbuster Drug Launch?
Motley Fool
Merck
sotatercept
PAH
Flag link:
Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Fierce Biotech
Merck
Acceleron
clinical trials
sotatercept
PAH
pulmonary arterial hypertension
Flag link:
Long after first nod for inhaled Tyvaso, United Therapeutics scraps PhIII in PH with COPD
Long after first nod for inhaled Tyvaso, United Therapeutics scraps PhIII in PH with COPD
Endpoints
Tyvaso
United Therapeutics
PAH
clinical trials
Flag link:
FDA declines to approve United-MannKind's lung disease therapy
FDA declines to approve United-MannKind's lung disease therapy
Yahoo/Reuters
MannKind
United Therapeutics
Tyvaso
FDA
PAH
Flag link:
Is an Acquisition of Acceleron a Smart Move for Merck?
Is an Acquisition of Acceleron a Smart Move for Merck?
Motley Fool
Merck
M&A
Acceleron
PAH
Keytruda
Flag link:
Merck & Co justifies paying up for Acceleron
Merck & Co justifies paying up for Acceleron
EP Vantage
Merck
Accleron
M&A
sotatercept
Reblozyl
PAH
Flag link:
Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug
Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug
BioSpace
Merck
Acceleron
M&A
PAH
Flag link:
Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report
Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report
Endpoints
Merck
Acceleron
M&A
PAH
sotatercept
Flag link:
MannKind and United Snag Priority Review for Pulmonary Hypertension Drug
MannKind and United Snag Priority Review for Pulmonary Hypertension Drug
BioSpace
MannKind
United Therapeutics
PAH
PH-ILD
FDA
priority review
Tyvaso
Flag link:
Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign
Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign
Endpoints
Acceleron
sotatercept
PAH
Flag link:
J&J aims to create community for PAH patients and their doctors with new Uptravi campaign
J&J aims to create community for PAH patients and their doctors with new Uptravi campaign
Fierce Pharma
JNJ
PAH
Uptravi
pharma marketing
Flag link:
United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback
United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback
Endpoints
United Therapeutics
Trevyent
PAH
SteadyMed
Flag link:
With pipeline setbacks mounting, United snares priority voucher for inhaled formulation of PAH med Tyvaso
With pipeline setbacks mounting, United snares priority voucher for inhaled formulation of PAH med Tyvaso
Endpoints
United Therapeutics
Tyvaso
priority review voucher
PAH
Flag link:
Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients
Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients
Pharmaceutical Business Review
Adempas
Bayer
PAH
clinical trials
Flag link:
Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status
Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status
Endpoints
Acceleron
PAH
FDA
breakthrough therapy
sotatercept
Flag link:
Pages
1
2
3
4
5
next ›
last »